Related Experiment Video
Updated: Aug 1, 2026
09:03
Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
Published on: November 23, 2014
Antiangiogenesis as a strategy for antimetastasis
1Department of Surgery, Children's Hospital, Boston, MA 02115.
Seminars in Thrombosis and Hemostasis
|January 1, 1988
Summary
Inhibiting angiogenesis, the formation of new blood vessels, is a promising strategy for cancer treatment. Blocking tumor vascularization effectively halts tumor growth and prevents metastasis.
Area of Science:
- Oncology
- Cell Biology
- Biomedical Research
Background:
- Angiogenesis is a vital physiological process involving new blood vessel formation.
- Tumor growth and metastasis are critically dependent on sustained tumor vascularization.
- Dysregulated angiogenesis is a hallmark of cancer, supporting tumor progression.
Purpose of the Study:
- To explore the role of angiogenesis in tumor growth and metastasis.
- To evaluate strategies targeting vascularization for cancer therapy.
- To understand the relationship between vascularization and tumor cell survival.
Main Methods:
- Review of current understanding of angiogenesis regulation.
- Analysis of the impact of vascularization inhibition on tumor tissue.
- Evaluation of anti-angiogenic strategies for antimetastasis.
Main Results:
- Tumor destruction is exponentially related to reduced vascularization.
- Interfering with new vessel proliferation significantly impedes tumor growth.
- Preventing vascularization is crucial for preventing dormant metastatic cells from forming secondary tumors.
Conclusions:
- Targeting angiogenesis is a viable therapeutic strategy for cancer treatment.
- Inhibiting tumor vascularization offers a potent approach for controlling tumor growth.
- Anti-angiogenic therapies hold significant promise for preventing cancer metastasis.
Related Concept Videos
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.